← Search & browse all drugs
BLOOD AND BLOOD FORMING ORGANS › ANTIANEMIC PREPARATIONS › OTHER ANTIANEMIC PREPARATIONS › Other antianemic preparations
molidustat
B03XA09
Forms & Strengths
- Tablets: 10mg, 25mg, 50mg, 100mg, 150mg
- Oral formulation
Adult Dosing
- Anemia in CKD: 50mg twice daily, adjust to 25mg or 100mg twice daily
- Maximum dose: 100mg twice daily
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
- Not recommended for patients under 18 years old
Indications
- Treatment of anemia in adult patients with chronic kidney disease (CKD)
- Correction of anemia in CKD patients not on dialysis
Mechanism of Action
- Selective inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PHD)
- Increases endogenous erythropoietin production
- Stimulates red blood cell production
Contraindications
- Hypersensitivity to molidustat
- Pregnancy and breastfeeding
- Severe hepatic impairment
Adverse Reactions
- Headache
- Nausea
- Vomiting
- Fatigue
- Dizziness
- Increased blood pressure
Drug Interactions
- Concomitant use with strong CYP3A4 inducers (e.g., rifampicin) decreases molidustat exposure
- Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) increases molidustat exposure
Curated Content: Needs Vetting Before Put to Clinical Use